- Two cancer drugmaker rivals presented data on Monday about how combinations of their drugs, which harness the body's immune system to treat cancer, worked in treating a common form of lung cancer compared to traditional chemotherapy.
- Merck showed that its drug Keytruda in combination with chemotherapy cut the risk of death in lung cancer patients in half.
ADVERTISEMENT
2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)
The markets picked Merck as the winner based on its data lung cancer. Merck's stock was up about 3% on Monday while BMS was down about 5%.
ADVERTISEMENT
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
Malak El Masry speaks on championing entrepreneurship and art in Africa
Junta led Burkina Faso suspends more foreign media over killings coverage
10 African countries with the strongest merchant marine fleet
Who are Africa's biggest Esports teams?
Top 10 strongest South African brands in 2024
The untapped potential of forex markets
African Hidden Champions Soirée highlights Africa's business leaders with support from AFG, DEG, AfDB, and BII
DalaPay forecasting new trends in African payment systems for 2024